Genus PLC Asset Resilience Ratio
Genus PLC asset resilience ratio. Genus PLC (GNS) has an Asset Resilience Ratio of -1.07% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Genus PLC to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Genus PLC (2006–2023)
Asset resilience ratio of Genus PLC from 2006 to 2023. This chart shows how Genus PLC's Asset Resilience Ratio has changed over time. Read debt load of Genus PLC for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Genus PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Genus PLC.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 0% |
| Short-term Investments | GBX-11.30 Million | -1.07% |
| Total Liquid Assets | GBX-11.30 Million | -1.07% |
Asset Resilience Insights
- Limited Liquidity: Genus PLC maintains only -1.07% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Genus PLC Industry Peers by Asset Resilience Ratio
Compare Genus PLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 15.21% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Immunovant Inc
NASDAQ:IMVT |
Biotechnology | 98.50% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Amicus Therapeutics Inc
NASDAQ:FOLD |
Biotechnology | 8.37% |
Genus PLC Asset Resilience Ratio by Year (2006–2023)
Genus PLC asset resilience ratio by year from 2006 to 2023. The table below shows the annual Asset Resilience Ratio data for Genus PLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-06-30 | -1.30% | GBX-13.10 Million ≈ $-1.59K |
GBX1.01 Billion ≈ $122.58K |
-0.24pp |
| 2022-06-30 | -1.06% | GBX-10.80 Million ≈ $-1.31K |
GBX1.02 Billion ≈ $123.85K |
-0.85pp |
| 2021-06-30 | -0.21% | GBX-1.80 Million ≈ $-219.01 |
GBX851.00 Million ≈ $103.54K |
0.00pp |
| 2020-06-30 | -0.21% | GBX-1.80 Million ≈ $-219.01 |
GBX855.40 Million ≈ $104.08K |
-0.53pp |
| 2018-06-30 | 0.32% | GBX2.50 Million ≈ $304.18 |
GBX789.20 Million ≈ $96.02K |
+0.15pp |
| 2017-06-30 | 0.16% | GBX1.30 Million ≈ $158.17 |
GBX797.60 Million ≈ $97.04K |
+0.08pp |
| 2016-06-30 | 0.08% | GBX600.00K ≈ $73.00 |
GBX739.10 Million ≈ $89.93K |
-0.03pp |
| 2015-06-30 | 0.11% | GBX700.00K ≈ $85.17 |
GBX644.30 Million ≈ $78.39K |
+0.18pp |
| 2012-06-30 | -0.07% | GBX-400.00K ≈ $-48.67 |
GBX588.20 Million ≈ $71.57K |
+0.10pp |
| 2010-06-30 | -0.17% | GBX-900.00K ≈ $-109.50 |
GBX542.40 Million ≈ $65.99K |
+0.18pp |
| 2009-06-30 | -0.34% | GBX-1.70 Million ≈ $-206.84 |
GBX497.90 Million ≈ $60.58K |
+0.23pp |
| 2008-06-30 | -0.57% | GBX-2.50 Million ≈ $-304.18 |
GBX436.00 Million ≈ $53.05K |
+0.46pp |
| 2007-06-30 | -1.03% | GBX-4.50 Million ≈ $-547.52 |
GBX434.80 Million ≈ $52.90K |
-0.38pp |
| 2006-06-30 | -0.66% | GBX-3.00 Million ≈ $-365.01 |
GBX456.30 Million ≈ $55.52K |
-- |
About Genus PLC
Genus plc produces and sells animal genetics to farmers in North America, Latin America, the United Kingdom, the rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It offers dairy and beef bull semen and embryos under the Genus and Bovec brands; breeding pork and semen, as well as techni… Read more